Results 121 to 130 of about 3,297 (182)
Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study. [PDF]
J ImmunolAbe K, Holmes TH, Nguyen TT, IMPACC Network
, Kim-Schulze S, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Schaenman J, Reed EF, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N, Maecker HT. +42 moreeuropepmc +1 more sourceEvaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch. [PDF]
JAMA NeurolBrown CA, Mundada NS, Cousins KAQ, Sadeghpour N, Lyu X, McGrew E, Korecka M, Chen-Plotkin A, Xie L, Wisse LEM, Detre JA, McMillan CT, Lee EB, Nasrallah IM, Das SR, Mechanic-Hamilton D, Yushkevich PA, Shaw LM, Wolk DA, Alzheimer’s Disease Neuroimaging Initiative. +19 moreeuropepmc +1 more sourceMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. [PDF]
Lancet OncolGillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW, STAMPEDE investigators. +53 moreeuropepmc +1 more source
